List of Excipients in Branded Drug CARBAGLU

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	CELLULOSE, MICROCRYSTALLINE
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	CROSCARMELLOSE SODIUM
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	HYPROMELLOSE
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	SILICON DIOXIDE
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	SODIUM LAURYL SULFATE
Recordati Rare Diseases	CARBAGLU	carglumic acid	52276-312	SODIUM STEARYL FUMARATE

CARBAGLU Excipient Strategy and Commercial Opportunities for Carglumic Acid

Last updated: August 27, 2026

Carbaglu is a specialized oral dispersible-tablet product containing 200 mg of carglumic acid. Its commercial value comes from treatment of rare metabolic disorders, limited diagnostic capacity, chronic-use potential in selected patients, and formulation requirements that create practical barriers for generic competitors. The strongest excipient opportunities are pediatric acceptability, rapid dispersion, dose flexibility, stability, and lower-cost manufacturing rather than new pharmacology.

What is Carbaglu and which patients does it treat?

Carbaglu contains carglumic acid, a synthetic structural analog of N-acetylglutamate. In the urea cycle, N-acetylglutamate activates carbamoyl phosphate synthetase I. Carglumic acid can therefore reduce ammonia accumulation in patients with specific metabolic defects.

The U.S. product is approved for:

• Acute and chronic hyperammonemia caused by N-acetylglutamate synthase, or NAGS, deficiency.
• Acute and chronic hyperammonemia caused by propionic acidemia, or PA.
• Acute and chronic hyperammonemia caused by methylmalonic acidemia, or MMA.

Carbaglu is administered as a tablet for oral suspension. Patients disperse the tablet in water before administration. The product is used in newborns, infants, children, adolescents, and adults, creating a broad set of formulation and administration requirements (U.S. Food and Drug Administration [FDA], 2023).

What is the dosage form?

The commercial dosage form is a 200 mg dispersible tablet. The tablet is intended to be dispersed in water rather than swallowed intact. This design supports administration to patients who cannot reliably swallow conventional tablets.

The product’s dosage-form requirements include:

Requirement	Commercial significance
Rapid dispersion in water	Important during acute hyperammonemia episodes
Dose flexibility	Relevant because dosing is weight-based and may change during treatment
Pediatric suitability	Supports use in neonates, infants, and young children
Acceptable taste and mouthfeel	Affects adherence during chronic treatment
Chemical stability	Important for long-term storage and repeated use
Reproducible dose delivery	Required for a high-risk metabolic disease
Low excipient burden	Valuable for medically fragile and pediatric patients

What excipients are used in Carbaglu?

The U.S. prescribing information identifies excipients including microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, hypromellose, mannitol, colloidal silicon dioxide, and sodium stearyl fumarate. The precise composition and terminology may differ across regional labels and manufacturing sites (FDA, 2023).

What does each excipient do?

Excipient	Likely functional role in the Carbaglu tablet
Microcrystalline cellulose	Diluent and compression aid
Croscarmellose sodium	Superdisintegrant supporting rapid dispersion
Sodium lauryl sulfate	Wetting agent that improves water penetration
Hypromellose	Binder or matrix-control excipient
Mannitol	Diluent, bulking agent, and potential mouthfeel modifier
Colloidal silicon dioxide	Glidant and flow aid
Sodium stearyl fumarate	Lubricant for tablet manufacture

The formulation is commercially logical for a dispersible tablet. Croscarmellose sodium, sodium lauryl sulfate, tablet porosity, and compression force must work together to produce a uniform suspension quickly. Excessive lubrication or over-compression could slow dispersion. Excessive surfactant could increase foaming, alter taste, or affect gastrointestinal tolerability.

Which excipient attributes matter most for a Carbaglu competitor?

A competing product must reproduce the clinical performance of the reference product while meeting pharmaceutical quality requirements. The main formulation risks are not limited to assay and dissolution.

Dispersion time

A generic or follow-on product should disperse rapidly in the labeled volume of water. This is particularly relevant during acute hyperammonemia, when caregivers or hospital personnel may administer treatment under time pressure.

The critical variables include:

• Tablet porosity.
• Particle-size distribution of carglumic acid.
• Level and grade of croscarmellose sodium.
• Surfactant concentration.
• Compression force.
• Water temperature and volume.
• Agitation method.
• Sedimentation after dispersion.

A formulation that meets ordinary tablet dissolution criteria but produces a slow or nonuniform suspension may have practical disadvantages in clinical use.

Dose uniformity and dose flexibility

Carglumic acid dosing is weight-based. Young patients may require fractions of a 200 mg tablet or multiple tablets dispersed together. A commercial opportunity exists for:

• Lower-strength tablets.
• Scored tablets validated for subdivision.
• Sachets or unit-dose powder presentations.
• Metered oral suspensions.
• Multiparticulate products.
• Caregiver-friendly preparation devices.

The regulatory burden increases as a product moves away from the reference dosage form. A lower-strength dispersible tablet may be commercially attractive but could require a separate strength, additional stability data, and new bioequivalence justification.

Taste and mouthfeel

Mannitol can support an acceptable mouthfeel, but the active ingredient and surfactant may still generate bitterness or an unpleasant aftertaste. Taste masking is commercially relevant because PA, MMA, and NAGS deficiency often require long-term treatment.

Potential strategies include:

• Ion-exchange resin complexes.
• Polymer-based taste-masking coatings.
• Lipid or lipid-polymer microparticles.
• Flavor systems compatible with pediatric metabolic disease.
• Ready-to-use suspensions with controlled sweetener levels.
• Microencapsulated carglumic acid.

Any taste-masking system must release carglumic acid promptly after administration. A coating that improves palatability but delays exposure could create a bioequivalence or clinical-performance problem.

Excipient tolerability

Patients with organic acidemias may have gastrointestinal instability and multiple dietary restrictions. Formulators should assess:

• Osmolality.
• Sorbitol and other polyol content.
• Sodium exposure.
• Gastrointestinal irritation from surfactants.
• Allergen and intolerance profiles.
• Preservative exposure in liquid products.
• Excipient accumulation in patients with renal or hepatic impairment.

A low-sodium, low-osmolality, preservative-minimized formulation could have a commercial advantage in pediatric and hospital settings.

What formulation patents protect Carbaglu?

Carbaglu’s principal commercial protection has historically relied on the carglumic acid product, orphan-drug exclusivity, regulatory approval, manufacturing know-how, trademarks, and market specialization rather than a large publicly prominent excipient patent estate.

The key patent questions are:

1. Whether any U.S. patents remain listed in the FDA Orange Book for the relevant Carbaglu NDA.
2. Whether patents cover the dispersible-tablet composition, manufacturing process, or medical use.
3. Whether regional patents remain active in Europe, Japan, Canada, or other markets.
4. Whether any patent claims specifically cover excipient combinations or dispersion performance.
5. Whether patents cover PA/MMA use separately from NAGS deficiency.

Publicly available regulatory materials identify the dosage form and inactive ingredients, but they do not establish that every listed excipient combination is patent-protected. Excipients such as microcrystalline cellulose, croscarmellose sodium, mannitol, colloidal silicon dioxide, and sodium stearyl fumarate are widely used pharmaceutical materials. A follow-on manufacturer would normally seek differentiation through formulation execution, manufacturing controls, and regulatory strategy rather than assuming broad exclusivity from the presence of those ingredients.

When did Carbaglu lose orphan exclusivity?

Carbaglu received U.S. approval for NAGS deficiency in 2010. The U.S. Orphan Drug Act provides seven years of orphan-drug exclusivity from approval for the designated indication. That period would have ended in 2017 for the original NAGS indication, subject to the specific FDA designation and approval record.

The PA/MMA indication was approved later. Any exclusivity associated with that approval would depend on the FDA designation, approval basis, and statutory exclusivity record for the supplement. Orphan exclusivity blocks approval of the same drug for the same orphan indication, but it does not create a general prohibition on all carglumic acid products.

Is there biosimilar risk for Carbaglu?

No. Carglumic acid is a small molecule, not a biologic. The relevant competitive pathway is an abbreviated new drug application, or ANDA, rather than a biosimilar application under the Public Health Service Act.

The main competitive risks are:

• Paragraph IV patent challenges.
• ANDA approval after expiration or resolution of listed patents.
• 505(b)(2) applications for modified formulations.
• Regional generic filings outside the United States.
• Compounded or hospital-prepared alternatives in limited circumstances.
• New oral liquid or pediatric presentations.

What Paragraph IV challenges and generic-entry risks exist?

A generic applicant could challenge any eligible Orange Book-listed patent through a Paragraph IV certification. The commercial value of such a challenge depends on:

• Remaining patent term.
• Scope of the claims.
• Whether claims cover the approved indication or dosage form.
• Strength of invalidity and noninfringement arguments.
• The size of the Carbaglu market.
• The cost of manufacturing carglumic acid.
• The risk of price erosion after entry.

For a rare-disease product, an ANDA applicant may have limited incentive to enter unless it can secure a high price, obtain orphan-market access, or supply multiple countries. The small patient population reduces sales potential, but the high value per patient can support niche generic economics.

What generic launch scenarios are most plausible?

Scenario	Likely market effect
Single generic tablet	Moderate price erosion; incumbent may retain specialist share
Multiple generic tablets	Greater discounting and payer pressure
Lower-strength pediatric product	Limited direct substitution but higher adherence value
Ready-to-use oral suspension	Potential convenience premium and hospital uptake
Powder or sachet product	Distribution and storage advantages
Compounded liquid	Local substitution but variable quality and stability
Global multi-market launch	Better manufacturing economics and supply-chain leverage

A generic tablet that matches the reference product may compete primarily on price. A modified formulation can compete on administration, but it may face a more complex regulatory path and could lose automatic substitution status.

What commercial opportunities exist in excipient and formulation development?

Pediatric liquid and ready-to-use formulations

The clearest opportunity is a stable, ready-to-use oral liquid with controlled dosing. Such a product could reduce caregiver preparation steps and improve hospital workflow.

Technical priorities include:

• Chemical stability in aqueous media.
• Microbial control.
• Accurate dosing at low volumes.
• Low sedimentation.
• Syringe compatibility.
• Acceptable taste without excessive sugar or polyol exposure.
• Packaging that limits moisture and oxygen exposure.

A liquid product could be positioned for neonatal and infant use, but its regulatory classification would determine whether it is an ANDA-equivalent product or a 505(b)(2) product.

Unit-dose sachets

A powder or granule sachet could improve portability and reduce tablet-handling errors. It could also support weight-based dosing through multiple strengths. The principal development risks are moisture sensitivity, segregation of active and excipients, and dispersion uniformity after reconstitution.

Taste-masked multiparticulates

Multiparticulates could be sprinkled into a compatible vehicle or administered through feeding systems. This format may help patients who cannot swallow tablets. Commercial differentiation would depend on:

• Rapid release.
• Low residual bitterness.
• Compatibility with enteral nutrition.
• Stability after opening.
• Dose uniformity across the container.
• Minimal clogging of feeding tubes.

Excipient substitution for supply-chain resilience

A second opportunity is a formulation that reduces dependence on specialized grades or vulnerable suppliers. Candidate substitutions should be assessed for:

• Equivalent functionality.
• Global regulatory acceptability.
• Availability across multiple regions.
• Impact on dispersion.
• Impact on tablet hardness and friability.
• Compatibility with high-speed compression.
• Stability under elevated temperature and humidity.

Excipient substitution can create a meaningful business advantage even without a new patent if it lowers manufacturing cost or reduces supply interruptions.

Hospital and specialty-pharmacy packaging

Carbaglu is suitable for packaging innovation because caregivers and specialty pharmacies manage repeated dosing. Opportunities include:

• Unit-dose blister cards.
• Child-resistant, moisture-protective packs.
• Reconstitution cups marked for the labeled water volume.
• Oral syringes calibrated for liquid presentations.
• QR-linked preparation instructions.
• Hospital emergency kits.

Packaging claims cannot replace drug-product protection, but they can improve adherence and create a differentiated commercial offering.

How does Carbaglu compare with competing ammonia-lowering therapies?

Carbaglu is differentiated from conventional ammonia-lowering agents because it targets a specific metabolic step and is used in inherited metabolic disease. Sodium benzoate, sodium phenylacetate, glycerol phenylbutyrate, and sodium phenylbutyrate have different mechanisms, formulations, sodium burdens, and administration profiles.

Product or therapy	Primary role	Formulation considerations	Competitive relationship
Carbaglu	Carglumic acid replacement or activation support	Dispersible tablet; pediatric administration	Direct product competition
Sodium benzoate	Nitrogen scavenger	High sodium burden; liquid or compounded formats	Adjunct or alternative in some settings
Sodium phenylacetate/benzoate	Acute ammonia reduction	Intravenous hospital use	Acute-care alternative
Glycerol phenylbutyrate	Chronic nitrogen scavenging	Oral liquid; taste and dosing issues	Chronic-care alternative
Sodium phenylbutyrate	Chronic nitrogen scavenging	Tablets or granules; sodium exposure	Alternative or adjunct

The commercial opportunity is strongest where the formulation solves an administration problem without compromising the metabolic-disease treatment pathway.

What is the FDA regulatory status and Orange Book position?

Carbaglu is an FDA-approved prescription drug marketed as a 200 mg tablet for oral suspension. Its U.S. regulatory record includes the original NAGS deficiency approval and later expansion to hyperammonemia associated with PA and MMA (FDA, 2023).

The Orange Book is the controlling source for current listed patents, exclusivity, therapeutic-equivalence evaluations, and NDA information. Patent status should be assessed by the specific NDA and current Orange Book edition because listed patents and delisting events can change over time (FDA, n.d.).

For commercial planning:

• An equivalent 200 mg dispersible tablet would generally target the ANDA pathway.
• A materially different liquid, sachet, or multiparticulate product may require a 505(b)(2) strategy.
• A formulation with a different route, indication, or dosing method may not qualify for automatic substitution.
• Orphan exclusivity must be assessed separately by indication.
• A patent challenge should be evaluated against the actual current Orange Book listing, not historic patent references.

Which companies control or challenge the market?

Recordati Rare Diseases is the principal commercial company associated with Carbaglu in the United States and international rare-disease markets. The company acquired rights to Carbaglu from UCB and has marketed the product within its rare-disease portfolio (Recordati, 2018).

The competitive landscape is fragmented by geography. Potential competitors include:

• Generic-drug manufacturers pursuing carglumic acid tablets.
• Specialty pharmaceutical companies developing pediatric oral liquids.
• Compounding pharmacies serving local hospital demand.
• Manufacturers of nitrogen-scavenging therapies.
• Rare-disease companies with metabolic-disorder distribution networks.

No biosimilar manufacturers are relevant. The important business question is whether a competitor can obtain reliable active-pharmaceutical-ingredient supply, validate a dispersible formulation, and reach metabolic specialists and specialty pharmacies at sufficient scale.

How strong is the Carbaglu patent and commercial estate?

The commercial estate is stronger in market specialization and clinical workflow than in obvious excipient exclusivity. Its practical defenses include:

• Rare-disease physician concentration.
• Diagnostic and treatment complexity.
• Specialist pharmacy distribution.
• Caregiver familiarity with the labeled preparation method.
• Limited global patient numbers.
• Potential manufacturing know-how.
• Regulatory friction for alternative pediatric dosage forms.
• Brand continuity in emergency metabolic care.

The weaker points are:

• Small-molecule generic eligibility.
• Expiration of the original orphan exclusivity period.
• Potentially limited formulation-patent breadth.
• Availability of standard pharmaceutical excipients.
• Possibility of modified-dose or liquid competitors.
• Price pressure from specialty payers and government programs.

A follow-on product should therefore seek a combined strategy: regulatory equivalence for rapid substitution where possible, plus formulation differentiation where price competition alone does not justify entry.

What revenue exposure and market opportunities matter?

Carbaglu revenue is not generally disclosed as a standalone public line item by its commercial owner. Exposure should be modeled using patient count, annual dose, net price, geographic mix, and persistence rather than relying on total rare-disease portfolio revenue.

The most valuable opportunities are likely to be:

1. A lower-cost equivalent tablet for the U.S. and European markets.
2. A pediatric liquid or granule product with superior administration.
3. A multi-country platform using a common carglumic acid formulation.
4. Contract manufacturing of dispersible tablets or sachets.
5. Specialty-pharmacy packaging and adherence services.
6. Supply-chain-secure excipient systems.
7. Hospital emergency-use presentations.

Key Takeaways

• Carbaglu is a 200 mg carglumic acid dispersible tablet used for NAGS deficiency and PA- or MMA-associated hyperammonemia.
• Its current excipient system supports tablet manufacture, wetting, rapid dispersion, and acceptable oral administration.
• Pediatric usability is the most important formulation opportunity.
• A ready-to-use liquid, sachet, lower-strength tablet, or taste-masked multiparticulate could create commercial differentiation.
• Carglumic acid is a small molecule, so generic competition is more relevant than biosimilar competition.
• The original seven-year U.S. orphan exclusivity period for NAGS deficiency would have ended in 2017.
• Current Orange Book listings must control any Paragraph IV or generic-entry analysis.
• Carbaglu’s strongest defenses are specialist distribution, rare-disease treatment familiarity, manufacturing know-how, and formulation execution.
• Revenue is likely concentrated in a small patient population with high per-patient treatment value.
• Excipient substitution and packaging improvements may provide commercial returns even without broad new patent protection.

FAQs About Carbaglu Excipient and Commercial Strategy

Can Carbaglu be reformulated as an oral suspension?

Yes, but a stable oral suspension would require control of chemical stability, microbial quality, dose uniformity, sedimentation, preservative exposure, and syringe dosing. The regulatory pathway would depend on how closely the product matches the approved reference product.

What is the most valuable new dosage form for carglumic acid?

A pediatric ready-to-use liquid or low-volume granule product is likely to offer the clearest administration advantage. The product must maintain rapid release and reliable dosing across neonatal and pediatric use conditions.

Can a generic manufacturer use the same Carbaglu excipients?

Generally, yes, subject to regulatory requirements, manufacturing controls, and intellectual-property review. The use of common excipients alone would not establish freedom to operate if valid claims cover a specific composition or manufacturing process.

Does Carbaglu require a biosimilar development program?

No. Carglumic acid is a chemically synthesized small molecule. A competitor would generally evaluate an ANDA or, for a materially different formulation, a 505(b)(2) application.

What is the largest barrier to generic Carbaglu entry?

The principal barriers are small market size, specialized active-ingredient supply, pediatric formulation validation, specialist distribution, and the need to demonstrate reliable dispersion and dose delivery. Patent and Orange Book issues remain product- and jurisdiction-specific.

References

1. Recordati. (2018). Annual report and corporate disclosures regarding Recordati Rare Diseases and Carbaglu. Recordati S.p.A.

2. U.S. Food and Drug Administration. (2023). Carbaglu (carglumic acid) tablets for oral suspension: Prescribing information. FDA.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Food and Drug Administration. (n.d.). Orphan Drug Act and orphan-drug exclusivity provisions. FDA.

5. European Medicines Agency. (n.d.). Carbaglu: EPAR product information. EMA.